SCHEDULE: Loewenbaum Group Amends CollPlant Holdings

The Loewenbaum Group has amended its Schedule 13D filing, disclosing a significant investment in CollPlant Biotechnologies Ltd. through a recent securities purchase agreement.

Summary

• The Loewenbaum Group, comprising several trusts and partnerships, has filed an amendment to its Schedule 13D regarding its holdings in CollPlant Biotechnologies Ltd.
• On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement to acquire 1,764,706 ordinary shares, Series A warrants for 1,764,706 shares, and Series B warrants for 3,529,412 shares.
• The transaction was completed on July 6, 2026.
• The Series A and Series B Warrants have an exercise price of $0.34 per share and are exercisable upon shareholder approval, expected around July 29, 2026.
• Series A Warrants expire on July 16, 2028, and Series B Warrants expire on July 16, 2031.
• The acquisitions are for investment purposes, with the intention to review the investment continuously and potentially take further actions.
• As of March 31, 2026, the Reporting Persons collectively beneficially owned 3,518,237 ordinary shares, representing 18.6% of the total outstanding ordinary shares, excluding shares underlying the warrants.
• The filing details the beneficial ownership of various individuals and trusts within the Loewenbaum Group.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating significant investor confidence and potential for future upside through warrant exercise, though contingent on shareholder approval.

Positives

• The Loewenbaum Group has made a significant investment in CollPlant Biotechnologies Ltd., indicating confidence in the company's prospects.
• The group has acquired a substantial stake, representing 18.6% of the outstanding ordinary shares as of March 31, 2026.
• The acquisition includes warrants, providing potential for increased ownership and upside participation.
• The exercise price for warrants is set at $0.34, which could be attractive depending on future share price performance.

Negatives

• The exercise of warrants is contingent on shareholder approval, introducing an element of uncertainty.
• The filing does not provide specific financial performance data for CollPlant Biotechnologies Ltd., making a direct assessment of the investment's current value difficult.

Risks

• The exercise of warrants is subject to shareholder approval, which may not be granted.
• Future investment decisions by the Reporting Persons are contingent on various factors including market conditions, company performance, and other opportunities, which could lead to changes in their stake.
• The value of the investment is subject to market fluctuations and the overall performance of CollPlant Biotechnologies Ltd.

Future Outlook

The Reporting Persons intend to review their investment in CollPlant Biotechnologies Ltd. on a continuing basis and may form plans to take actions specified in Schedule 13D clauses (a) through (j) depending on market conditions, company developments, and other factors.

Industry Context

StockSavvy.ai notes that significant stake acquisitions and warrant issuances are common in the biotechnology sector, often signaling a belief in future growth or a strategic move by investors to gain influence or profit from potential upside.

Stakeholder Impact

• Shareholders: The acquisition and potential future actions by the Loewenbaum Group could influence share price and corporate strategy.
• Management of CollPlant Biotechnologies Ltd.: The increased stake and potential for future actions by a significant investor may require engagement and strategic alignment.

Next Steps

• Shareholder approval for warrant exercisability, expected around July 29, 2026.
• Continuous review of investment by the Reporting Persons.
• Potential future amendments to Schedule 13D if plans for further action are formed.

Key Dates

Recommendation

The filing indicates a significant investment and potential for future upside, but the contingent nature of warrant exercise and the lack of detailed company performance metrics warrant a 'hold' position pending further developments and clarity on CollPlant's operational progress.

Keywords

CollPlant Biotechnologies, Schedule 13D, Securities Purchase Agreement, Warrants, Beneficial Ownership, Investment, Ordinary Shares, Shareholder Approval